Meeting
2017 ASCO Annual Meeting
Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors for fatal outcome.
Authors
Terufumi Kato
Kanagawa Cancer Center, Yokohama, Japan
Terufumi Kato , Fumikazu Sakai , Tomohisa Baba , Masahiko Kusumoto , Hirotsugu Kenmotsu , Hiroaki Sugiura , Junya Tominaga , Katsunori Oikado , Masafumi Sata , Masahiro Endo , Noriyo Yanagawa , Shinichi Sasaki , Tae Iwasawa , Yoshinobu Saito , Yutaka Fujiwara , Yuichiro Ohe , Yoshihiko Ito , Yasuhiro Tahara , Kazuyoshi Kuwano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9077)
DOI
10.1200/JCO.2017.35.15_suppl.9077
Abstract #
9077
Poster Bd #
403
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Pre-existing interstitial lung abnormalities are independent risk factors for interstitial lung disease during durvalumab treatment after chemoradiotherapy in patients with locally advanced non–small lung cancer.
First Author: Wakako Daido
Poster
2017 ASCO Annual Meeting
Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors using interim results of post-marketing all-case surveillance.
First Author: Hirotsugu Kenmotsu
Poster
2024 ASCO Annual Meeting
Cost-effectiveness of a circulating tumor fraction molecular biomarker for treatment response monitoring.
First Author: Zachary Rivers
Poster
2023 ASCO Annual Meeting
Incidence, risk factors, and outcomes of immune-related adverse events (irAEs) in a prospective, pan-tumor population.
First Author: Aanika Balaji